Kymera Therapeutics to Present at Upcoming February Investor Conferences

Rhea-AI Summary

Kymera Therapeutics (NASDAQ: KYMR) has announced its participation in two investor conferences. The conferences include the Guggenheim Healthcare Talks 2021 Oncology Day on February 11 at 1:30 p.m. ET and the BMO BioPharma Spotlight Series on February 18 at 10:30 a.m. ET. Both events will feature live webcasts available on the company’s website, with archived replays accessible for approximately 90 days. Kymera focuses on targeted protein degradation, offering innovative solutions for immune-inflammatory diseases and cancers through its Pegasus™ platform.

WATERTOWN, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will present at two upcoming investor conferences:

• Guggenheim Healthcare Talks 2021 Oncology Day on Thursday, February 11 at 1:30 p.m. ET
• BMO BioPharma Spotlight Series: “Proteins - Degraders and Other Next Gen Technologies” on Thursday, February 18 at 10:30 a.m. ET

A live webcast of each event will be available under "Events and Presentations" in the Investors section of the Company's website at www.kymeratx.com. Archived webcast replays of the presentations will also be available on the website for approximately 90 days.

About Kymera Therapeutics
Kymera Therapeutics is a biopharmaceutical company focused on advancing the field of targeted protein degradation, a transformative new approach to address previously intractable disease targets. Kymera’s Pegasus™ targeted protein degradation platform harnesses the body’s natural protein recycling machinery to degrade disease-causing proteins, with a focus on undrugged nodes in validated pathways currently inaccessible with conventional therapeutics. Kymera is accelerating drug discovery with an unmatched ability to target and degrade the most intractable of proteins, and advance new treatment options for patients. Kymera’s initial programs target IRAK4, IRAKIMiD, and STAT3 within the IL-1R/TLR or JAK/STAT pathways, providing the opportunity to treat a broad range of immune-inflammatory diseases, hematologic malignancies, and solid tumors. For more information, visit www.kymeratx.com.

Investor Contact:
Paul Cox
VP, Investor Relations and Communications
pcox@kymeratx.com
917-754-0207

Media Contact:
Lissette L. Steele
Verge Scientific Communications for Kymera Therapeutics
lsteele@vergescientific.com
202-930-4762

FAQ

What upcoming investor conferences will Kymera Therapeutics attend in February 2021?

Kymera Therapeutics will present at the Guggenheim Healthcare Talks 2021 Oncology Day on February 11 at 1:30 p.m. ET and the BMO BioPharma Spotlight Series on February 18 at 10:30 a.m. ET.

Where can I watch the webcasts for Kymera Therapeutics' presentations?

The live webcasts for Kymera Therapeutics' presentations will be available in the 'Events and Presentations' section of their website.

What is the focus of Kymera Therapeutics' drug development?

Kymera Therapeutics focuses on targeted protein degradation to develop treatments for immune-inflammatory diseases and cancers.

What innovative platform does Kymera Therapeutics use for drug discovery?

Kymera Therapeutics uses its Pegasus™ targeted protein degradation platform to advance drug discovery.

How long will the archived webcasts of Kymera Therapeutics' presentations be available?

Archived webcasts of Kymera Therapeutics' presentations will be available for approximately 90 days.